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Drp1Parkinson's disease (PD) is a neurodegenerative disorder for which available treatments provide symptom
relief but do not stop disease progression. Mitochondria, and in particular mitochondrial dynamics, have
been postulated as plausible pharmacological targets. Mitochondria-targeted antioxidants have been devel-
oped to prevent mitochondrial oxidative damage, and to alter the involvement of reactive oxygen species
(ROS) in signaling pathways. In this study, we have dissected the effect of MitoQ, which is produced by
covalent attachment of ubiquinone to a triphenylphosphonium lipophilic cation by a ten carbon alkyl
chain. MitoQ was tested in an in vitro PD model which involves addition of 6-hydroxydopamine (6-OHDA)
to SH-SY5Y cell cultures. At sublethal concentrations of 50 μM, 6-OHDA did not induce increases in protein
carbonyl, mitochondrial lipid peroxidation or mitochondrial DNA damage. However, after 3 h of treatment,
6-OHDA disrupts the mitochondrial morphology and activates the machinery of mitochondrial ﬁssion, but
not fusion. Addition of 6-OHDA did not increase the levels of ﬁssion 1, mitofusins 1 and 2 or optic atrophy
1 proteins, but does lead to the translocation of dynamin related protein 1 from the cytosol to the mitochon-
dria. Pre-treatment with MitoQ (50 nM, 30 min) results in the inhibition of the mitochondrial translocation
of Drp1. Furthermore, MitoQ also inhibited the translocation of the pro-apoptotic protein Bax to the mito-
chondria. These ﬁndings provide mechanistic evidence for a role for redox events contributing to mitochon-
drial ﬁssion and suggest the potential of mitochondria-targeted therapeutics in diseases that involve
mitochondrial fragmentation due to oxidative stress.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is the second most prevalent neurode-
generative disorder. At present, common medications provide some
dramatic relief of the symptoms but fail to abrogate disease develop-
ment. Unfortunately, efforts to ﬁnd effective agents that provide pro-
tection against neurodegeneration have been rather unsuccessful [1].
Oxidative stress, resulting from an imbalance between generation of
reactive oxygen species (ROS) and antioxidant mechanisms, is an im-
portant factor in the etiology and pathogenesis of degenerative dis-
eases. Besides their importance for bioenergetics, mitochondria are
involved in oxidative damage and cell signaling leading to cell death
through the generation of ROS. Therefore, mitochondrial dysfunction
is central to a broad range of pathologies [2–5].ología Traslacional, Complejo
lcó 37, 02006 Albacete, Spain.
lindo).
l rights reserved.There are a series of mitochondrial antioxidant defenses for inter-
cepting ROS and minimizing oxidative damage. But, excessive produc-
tion of ROS or disruption of the antioxidant defenses leads to
extensive oxidative damage of themitochondria [6]. Pathology, toxicol-
ogy, and genetics suggest mitochondrial oxidative stress as an etiologi-
cal cause in PD [7,8]. A plausible general therapeutic approach thus
could be the reduction of mitochondrial oxidative damage [6,9]. A num-
ber ofmitochondria-targeted therapies are being developed [10], in par-
ticular antioxidants conjugated to triphenylphosphonium cation (TPP)
such as mitoquinone, mitovitamin E and mitophenyltertbutyline [11].
The best characterized mitochondria-targeted antioxidant is MitoQ
([10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]
triphenylphosphonium), which consists of a ubiquinone moiety that is
linked to a TPP cation by a 10-carbon alkyl chain [12]. MitoQ accumulates
within the mitochondria and, once it is there, is continually recycled to
the active ubiquinol antioxidant by complex II of the respiratory chain
[12,13]. MitoQ has been used to prevent mitochondrial oxidative
damage and to block the involvement of ROS in signaling pathways
[12,13]. MitoQ functionsmost likely through its direct antioxidant action,
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been shown [14–16]. MitoQ has been developed as a therapy for humans
and has undergone clinical trials [17,18].
Different experimental models have proved effective in the search
for clues to the underlying cause of Parkinson's Disease (PD) [19], for
instance, the administration of 6-hydroxydopamine (6-OHDA) to ex-
perimental animals or cell cultures [20]. However the mechanisms by
which 6-OHDA elicits its neurotoxic effects have yet to be fully eluci-
dated, although a role for oxidative stress (reviewed in [2]) and the
participation of mitochondrially-mediated cell death [21], including
morphological alterations of mitochondria such as fragmentation
[22] are likely.
Mitochondria undergo continuous ﬁssion, fusion and movement re-
ferred to asmitochondrial dynamics.Major neurodegenerative diseases,
including PD, involve disruption of mitochondrial dynamics. These
structural abnormalities are caused by an imbalance in highly conserved
GTPase genes, which are essential for mitochondrial ﬁssion and fusion.
GTPase dynamin-related protein-1 (Drp1), ﬁssion 1 (Fis1), mitofusins
1 and 2 (Mfn1, Mfn2), and optic atrophy 1 (Opa1) proteins —regulate,
maintain and remodel mammalian mitochondria [23,24]. Remarkably,
in several disease models, the manipulation of mitochondrial fusion or
ﬁssion can partially rescue disease phenotypes [23,25]. Therefore, inter-
ference with those early processes may yield a neuroprotective ap-
proach. Recent studies reported that impaired mitochondrial dynamics
involve the participation of Drp1 in different neurodegenerative disease,
including Alzheimer's [25,26] and Huntington's [24,27]. In addition, in a
previous study, we have shown that in an in vitro pharmacological
model of Parkinson's disease, 6-OHDA disrupts mitochondrial dynamics
by inducing mitochondrial fragmentation. In this case activation of the
mitochondrial ﬁssion machinery was monitored by assaying the trans-
location of Drp1 from the cytosol to the mitochondria [22]. The translo-
cation of Drp1 to the mitochondria took place very early in the process,
before apoptotic hallmarks such as collapse of the mitochondrial mem-
brane potential or cytochrome c release become apparent, and was ac-
companied by formation of Bax foci on the mitochondrial surface [21].
In the present study we found that MitoQ dramatically diminished
6-OHDA-induced mitochondrial fragmentation. Through its capacity to
alter mitochondrial redox processes MitoQ seems to exert its effects
by preventing the migration of Drp1 and Bax to mitochondria.
2. Material and methods
2.1. Reagents and plasmids
DMEM-F12, penicillin–streptomycin, gentamicin and fetal bovine
serum (FBS) were purchased from Gibco-Invitrogen. 6-OHDA from
SIGMA. The BCA protein assay kit from PIERCE. The pDsRed2-mito vec-
tor was provided by Clontech, Drp1-GFPwas provided by T.Wilson and
Dr. S. Strack, Dept. Pharmacology, University of Iowa Carver College of
Medicine. GFP-Bax was a gift from Dr. J.H.M. Prehn (Department of
Physiology and RCSI Neuroscience Research Centre, Royal College of
Surgeons, Ireland).
2.2. Cell culture and drug treatment procedures
SH-SY5Y cell lineswere obtained from theAmerican TypeCulture Col-
lection (ATCC). Cell cultures were grown as described previously [28] in
Dulbecco's modiﬁed Eagle's medium (DMEM-F12) supplemented with
2 mM L-glutamine, 20 units·mL−1 penicillin-streptomycin, 5 mg·mL−1
gentamicin and 15% (v/v) FBS. Cellswere grown in a humidiﬁed cell incu-
bator at 37 °C under a 5% CO2 atmosphere. Cells were plated 24 h before
transfection at a density of 5.3×104 cells cm−2, on μ-dish-35 mm Ibidi
GmbH (Munich, Germany). 6-OHDA was added to culture medium at a
ﬁnal concentration of 50 μM. Duration of pre-treatment with MitoQ and
TPP was 30 min and were maintained during the whole experiments.2.3. Transfections
Twenty-four hours before transfection, cells were plated at a den-
sity of 5.3×104 cells cm−2 on μ-dish-35 mm Ibidi GmbH (Munich,
Germany). Transfection was achieved using Lipofectamine reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer's pro-
tocol. Cells were transfected with plasmids encoding pDsRed2,
Drp1-GFP, and Bax-GFP. After 4 h of incubation the transfection mix-
ture was removed and replaced with fresh complete medium. To
allow protein expression, further experiments were performed 24 h
after transfection.
2.4. Image acquisition and processing
Micrographs were processed with Huygens Deconvolution Soft-
ware (Scientiﬁc Volume Imaging) and Adobe Photoshop. For quanti-
tative analysis of mitochondrial morphology, the three patterns of
mitochondrial morphology (ﬁlamentous, punctuate or intermediate)
were recorded in at least 100 cells per coverslip observed on adjacent
ﬁelds at magniﬁcation 63×. We assessed the robustness of this classi-
ﬁcation by comparing data obtained with separate cover slips from
the same experiment and from successive passages. In addition, the
monitoring of the mitochondrial morphology was performed by two
independent examiners on three different cultures. The proportions
observed were similar in all these experiments demonstrating that
mitochondrial morphology could be reliably analyzed and did not
vary within and between experiments under basal culture conditions.
We performed the experiments using a “blind” counter.
2.5. Analysis of mitochondrial morphology
Cells were transfected with pDsRed2-Mito, which leads to the ex-
pression of ﬂuorescent DsRed2 in mitochondria, thereby labeling the
organelles. The transfected cells are then subjected to experimental
treatments to evaluate mitochondrial morphology by ﬂuorescence
microscopy. For quantiﬁcation, the percentage of cells with abnormal
mitochondrial morphologies was determined and taken as a measure
of the proportion of cells with fragmented mitochondria. Most of the
cells had either fragmented or ﬁlamentous mitochondria, whereas a
small percentage (b10%) of the cells contained both fragmented and
ﬁlamentous mitochondria. In case of the latter, the mitochondrial
morphology was classiﬁed according to the majority (>70%) of the
mitochondria.
2.6. Protein carbonyl determination
SH-SY5Y cells were cultured in 150 mm Dish plates until they
were conﬂuent. Then, cells were scraped off, resuspended in cold
PBS, and centrifuged in Eppendorf tubes for 5 min at 12,000 rpm.
After this, supernatants were discarded and the pellets were
resuspended in 300 μL of cold PBS and sonicated. Protein Carbonyls
were assayed by ELISA, using a commercial kit (BioCell Corp., New
Zealand) and following the manufacturer's instructions. Protein was
quantiﬁed with the BCA Protein Assay Reagent (Pierce). Samples
were assayed in triplicate using protein carbonyl and BSA protein
standards that are supplied with the kit.
2.7. Measurement of mtDNA damage and copy number
SH-SY5Y cells were grown in 6-well plates at a conﬂuence of
700,000 cells well−1. The following day, cells were exposed to drugs
for 3 h after which the spent medium was removed and cells were
scraped off, resuspended in 0.5 mL of cold PBS, and transferred to
Eppendorf tubes. The cell suspensions were centrifugated for 3 min at
12,000 rpm, and the pellet was resuspended in 200 μL of cold PBS.
Total DNA was isolated from these cells using the Qiagen DNeasy
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dsDNA assay kit (Invitrogen) and a SpectraMax ﬂuorimetric plate read-
er (excitationwavelength 488 nm, emissionwavelength 515 nm). DNA
was then diluted to 3 ng/μL in TE buffer (10 mM Tris, 1 mM EDTA,
pH 7.5) and stored at−20 °C.
Damage to mtDNA was assayed using a PCR method which mea-
sures the ampliﬁcation of a very long (∼10 kb) section of mtDNA.
Damage to the mtDNA (e.g. strand breaks, abasic sites, and certain
types of oxidative lesions) blocks the progression of the DNA poly-
merase, thus decreasing ampliﬁcation. To control for mtDNA copy
number, ampliﬁcation of the long DNA target was normalized to
that of a short (126 bp) mtDNA region. Ampliﬁcation of a short
mtDNA target is ∼100-fold less likely to be affected by random dam-
age, allowing for comparison of DNA damage between different
samples.
PCR primers were modiﬁed from published ones. The long mtDNA
target encompasses nt 3278 to nt 13343 (10,065 bp; ND1 to ND5).
The forward primer was 5′‐TCTAAGCCTCCTTATTCGAGCCGA‐3′ and
the reverse primer was 5′‐TTTCATCATGCGGAGATGTTGGATGG‐3′.
The short DNA target for ampliﬁcation spans the region from nt
3278 to nt 3404 (126 bp; ND1). The reverse primer was the same as
for the long mtDNA target and the forward primer was 5′‐
CCCCACAAACCCCATTACTAAACCCA‐3′. Primers were synthesized by
Sigma-Genosys, diluted to 10 μM in TE buffer, and stored as aliquots
at −20 °C. PCRs were performed using the GeneAmp XL PCR kit
(Applied Biosystems) in a total volume of 50 μL, consisting of 15 ng
DNA template, 1 U rTth DNA polymerase XL, and 35 μL PCR master
mix containing 5 μg BSA, 200 μM dNTPs, 20 pmol forward primer,
20 pmol reverse primer, and 1.0 mM magnesium acetate (0.9 mM
for the short mtDNA target). The PCR was initiated with a manual
hot start by heating the mixture to 75 °C before adding the DNA po-
lymerase. The PCR parameters were, for the short mtDNA target,
18 cycles of 30 s at 94 °C, 45 s at 60 °C, and 45 s at 72 °C followedA
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Fig. 1. 6-OHDA does not induce large scale mitochondrial oxidative damage. A. Protein carbon
B. MtDNA integrity following a 3 h treatment with 6-OHDAwas determined by semi-quantitat
idation was determined by calculating the oxidation of MitoPerOx within cells. The concentra
590 nm is shown in the bar graph. Given values are the mean±SEM of ﬁve independent exp
post hoc Tukey).by 10 min at 75 °C. For the long mtDNA target the conditions were:
1 min at 94 °C, followed by 19 cycles of 15 s at 74 °C and 12 min at
64 °C followed by a ﬁnal extension step of 10 min at 72 °C. PCR prod-
ucts were quantiﬁed by the PicoGreen assay. Ampliﬁcation linearity
was tested by adding controls with 25% or 50% of the amount of
DNA template. The reaction was considered linear if the ampliﬁcation
obtained in the controls was between 40% and 60%. All samples
were ampliﬁed in duplicate and corrected for the control without
template.
2.8. Preparation of mitochondrial fractions
Cells werewashedwith ice-cold PBS, left on ice for 10 min, and then
resuspended in isotonic homogenization buffer (250 mM sucrose,
10 mM KCl, 1.5 mMMgCl2, 1 mM sodium-EDTA, 1 mM sodium-EGTA,
1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl ﬂuoride, and
10 mM Tris–HCl, pH 7.4) containing a proteinase inhibitor mixture
(Roche, Basel, Switzerland). After 40 strokes in a Dounce homogenizer,
the unbroken cells were spun down at 30 g for 5 min. Themitochondri-
al fractions were fractionated at 750 g for 10 min and 14,000 g for
20 min, respectively, and separated from the supernatant (cytosolic
fraction).
2.9. Western blotting
For measurements of cellular concentrations of Mfn1, Mfn2, Opa1,
Fis1, Drp1 and Bax, cells were washed with PBS and lysed for 5 min in
30 μL ofﬁce-cold lysis buffer, consisting of 80 mMKCl, 250 mMsucrose,
500 μg/mL digitonin, and 1 μg/mL each of the protease inhibitors
leupeptin, aprotinin, pepstatin, and 0.1 mM PMSF in PBS. Cell lysates
were centrifuged for 5 min at 10,000 g. Protein concentrations were
quantiﬁed spectrophotometrically (Micro BCA Protein Reagent Kit;
Pierce, Rockford, IL), and equal amounts of protein (30 μg) were loaded0.00
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ferred to polyvinylidene diﬂuoride membranes (Immobilon; Millipore
Corporation, Billerica, MA). Nonspeciﬁc protein binding was blocked
with Blotto (4% w/v nonfat dried milk, 4% bovine serum albumin
(Sigma), and 0.1% Tween 20 (Sigma)) in PBS for 1 h. The membranes
were incubated with anti-Fis1 (Atlas Antibodies 1:500), anti-
Mfn1(Santa Cruz; 1:1000 dilution), anti-; Mfn2 (abcam;1:1000 dilu-
tion), anti-Opa1(BD; 1:1000 dilution), anti-Bax (Cell Signaling 1:1000
dilution), anti-COX IV (Cell signaling; 1:1000dilution), anti-α-
Tubuline (Santa Cruz; 1:1000) and anti-Drp1 (BD Biosciences 1:1,000
dilution) overnight at 4 °C. After washing with Blotto, the membranes
were incubated with a secondary antibody (1:5000 dilution of a
peroxidase-conjugated from Promega, Madison, WI) in Blotto. TheControl dTPP MitoQ
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2.10. Mitochondrial viability
Mitochondrial viability was assessed in the SH-SY5y cells from con-
trol and experimental treatments (n=3) themitochondrial-dependent
reduction of 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetraz9olium
bromide (MTT) to formazan. Brieﬂy, in this reduction SH-SY5Y cells
were seeded in 48-well plates at a density of 105 cells per well. After
treatments, MTT (5 mg/mL in PBS) was added to the plates, and the
cells (control and experimental) were incubated for 1 h. The medium
was then replaced with DMSO, and MTT absorption was measured atF 6-OHDA+MitoQ
B 6-OHDA
D 6-OHDA+dTPP
ells were transfected with the pDsRed2-mito vector. Twenty-four hours later cells were
th 50 μM 6-OHDA. Representative confocal images of mitochondrial morphology under
gmented mitochondrial patterns were determined after a 3 h treatment with 6-OHDA.
nce was determined by a two-tailed Student's test: n/s, p>0.05; **pb0.01; ***pb0.001.
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Fig. 3. 6-OHDA does not induce mitochondrial fusion. Protein expression levels of Opa1
(A) Mfn1 (B), Mfn2 (C), and Fish1 (D) in lysates prepared from total cellular extracts
were subjected to immunoblotting. Equal amounts of protein (30 μg/lane) were loaded
on the gels. α-Tubulin levels were used as an index of total cell load. The immunoblots
shown are representative of three independent experiments.
178 M.E. Solesio et al. / Biochimica et Biophysica Acta 1832 (2013) 174–182570 nm. Resultswere expressed as the percentage ofMTT reduction, as-
suming that the absorbance of the control SH-SY5Y cells was 100%.
2.11. Intracellular lipid peroxidation measurement
SH-SY5Y cells were plated at a density of 5.3 104 cells/cm2 on μ-dish
35 mm plates obtained from IBIDI GmbH, (Munich, Germany).
Twenty-four hours later, the cells were treated with 6-OHDA, (100 or
50 μM) for 2.5 h after which the medium was refreshed by adding
fresh medium with the same concentration of 6-OHDA plus 100 nM
MitoPerOx [29], and incubating the plates for 30 min at 37 °C in the
dark. Then, plates were washed three times with 1× PBS and 1 mL
HEPES was added. Cells were visualized with a Zeiss Confocal Micro-
scope, using a 63× oil-immersion objective. In each ﬁeld, two different
photos were taken: one at 520 nm and one at 590 nm.We analyzed sig-
niﬁcant regions of interest fromall the photos, using ImageJ, and calculat-
ed the 520/590 nm ratio, which is a good measure of lipid peroxidation
production. In the presence of intracellular lipid peroxidation, there is
an increment in the 520 nm emission while 590 nm decreases.
3. Results
Addition of 6-OHDA to SH-SY5Y cell cultures is an in vitro experi-
mental model of PD. In this study, we have determined the effect of
the mitochondria-targeted antioxidant MitoQ on mitochondrial frag-
mentation in this model. We chose 50 μM 6-OHDA because 3 h of
treatment with this concentration is non-lethal but does alter mito-
chondrial morphology [22].
3.1. 6-OHDA has minimal effects on mitochondrial oxidative damage
Oxidative stress is a condition inwhich ROS production overwhelms
antioxidant defenses. Its occurrence can be detected by determining the
levels of protein carbonyl groups or the presence of oxidativemitochon-
drial DNA damage. The levels of protein carbonyl groups were deter-
mined in SH-SY5Y cells that had been challenged with 6-OHDA
(50 μM, 3 h). 6-OHDAdid not increase the total cellular levels of protein
carbonyl groups (Fig. 1A). In addition, we determined the effect on
mtDNA damage and deletion. Again, 6-OHDA did not disrupt mtDNA
(Fig. 1B). Taken together, we conclude that SH-SY5Y cells that were
challenged for 3 h with 50 μM 6-OHDA present do not undergo exten-
sive oxidative damage. In a third approachwe used the ratiometricﬂuo-
rescent probe MitoPerOx for assessing mitochondrial phospholipid
peroxidation within living cells [29]. Three hours after 6-OHDA addi-
tion, no signiﬁcant differences were found between cell cultures chal-
lenged or not with 50 μM 6-OHDA (Fig. 1C). Of note, when we
performed similar experiments with a higher concentration of 100 μM
6-OHDA, increases in all the oxidative hallmarks mentioned above
were found. Taken together, we conclude that SH-SY5Y cells that
were challenged for 3 h with 50 μM 6-OHDA present do not undergo
extensive oxidative damage and suggest that a relativelymild redox sig-
naling process can initiate mitochondrial ﬁssion. In addition, 3 h after
treatment, 50 μM 6-OHDA did not compromise the mitochondrial via-
bility of SH-SY5Y cells, as measured using the MTT assay (data not
shown).
3.2. MitoQ abrogates 6-OHDA-induced mitochondrial ﬁssion
Our previous work has shown that 6-OHDA induces mitochondrial
ﬁssion in SH-SY5Y cell cultures [22]. In the current study, to be able to
determine mitochondrial morphology, we have used the pDsRed2-
mito plasmid to express the mitochondrial protein DsRed2 (Fig. 2). As
expected, control cells contained elongated mitochondria. Addition of
50 μM 6-OHDA resulted in morphologically altered mitochondria, with
apparently shorter ﬁlaments (Fig. 2B, also see [22]). Quantitative analy-
sis revealed that 6-OHDA resulted in an increase in the proportion ofcells with mitochondrial morphology alterations, being 24% (pb0.001)
after 3 h of treatment (Fig. 2B, G).
In order to ascertain the role of mitochondrial oxidative events in
this process, we used the mitochondria-targeted antioxidant MitoQ.
First, we tested if the presence of the control compound dTPP,
which has the same mitochondria-targeting motif as MitoQ but
which lacks its antioxidant properties, has any effect on mitochondri-
al morphology. Control cell cultures expressing DsRed2 did not show
mitochondrial alterations after 3 h of dTPP (50 nM) treatment
(Fig. 2C, G). In addition, a 30 min pre-treatment with 50 nM of
dTPP did not decrease the percentage of cells showing fragmented
mitochondria after 3 h of treatment with 6-OHDA (Fig. 2C, G). Fur-
thermore, the mitochondrial morphology of cells under control con-
ditions was unaffected by the addition of 50 nM MitoQ (Fig. 2E, G).
Subsequently, cell cultures that were pre-treated for 30 min with
50 nM MitoQ were challenged with 50 μM 6-OHDA. Upon 3 h of
6-OHDA treatment, MitoQ signiﬁcantly decreased the number of
cells with fragmented mitochondria (Fig. 2F, G).3.3. 6-OHDA activates ﬁssion but not fusion of mitochondria
Mitochondrial fusion is controlled by three dynamin-related
GTPases: Mfn1 and Mfn2, in the outer mitochondrial membrane,
and Opa1 in the inner mitochondrial membrane. To determine
whether the change in mitochondrial morphology was due to an in-
crease in mitochondrial fusion, we explored the protein expression
levels of these three GTPases. Lysates from SH-SY5Y cells that had
been challenged with 50 μM 6-OHDA were compared with control
cells analyzed by immunoblotting. After 3 h of treatment, all the
GTPase proteins assayed had similar expression levels under both
conditions (Fig. 3A–C).
In the next set of experiments, we ascertained the role of Fis1 and
Drp1, two proteins that are involved in mitochondrial ﬁssion, in this
model. Levels of the outer mitochondrial membrane protein Fis1
were unaltered upon a 3 h treatment with 50 μM 6-OHDA (Fig. 3D).
Drp1 is a cytosolic protein that migrates to mitochondria to induce
mitochondrial ﬁssion [30]. SH-SY5Y cells were transfected with the
ﬂuorescent chimeric protein GFP-Drp1, which enables us to monitor
the intracellular localization of Drp1 using confocal microscopy.
Untreated cells showed cytosolic localization of GFP-Drp1 (Fig. 4A).
Upon a 3 h treatment with 50 μM 6-OHDA, a punctuated distribution
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translocated to the mitochondria (Fig. 4B, G).3.4. MitoQ reduces 6-OHDA-induced mitochondrial translocation of Drp1
Next, we determined the percentage of cellswith a punctate distribu-
tion of Drp1 following pre-treatment for 30 min with 50 nM MitoQ be-
fore challenge with 50 μM 6-OHDA. MitoQ reduced the number of cells
with a punctate appearance of Drp1 by about 74% in 6-OHDA-
challenged SH-SY5Y cell cultures (Fig. 4F, G). In addition, 50 nM dTPP
failed to induce Drp1 translocation in control cultures, and did not pre-
vent the 6-OHDA-induced effect on Drp1 localization (Fig. 4D, G).3.5. MitoQ reduces 6-OHDA-induced mitochondrial translocation of Bax
Previously, we have reported that the intracellular localization of
the pro-apoptotic protein Bax changes after 12 h treatment with
6-OHDA [21]. In the next set of experiments, we investigated if this
effect is modulated by MitoQ. Cell cultures were transfected with
GFP-Bax, and 24 h later they were pre-treated with either 50 nM
dTPP or MitoQ for 30 min, followed by addition of 50 μM 6-OHDA
(Fig. 5). After 12 h of 6-OHDA treatment, we determined the percent-
age of cells with punctate GFP-Bax distribution (Fig. 5G). The addition
of dTPP did not modify the cellular localization of Bax in control cul-
tures, and did not abrogate the effects of 6-OHDA (Fig. 5C–D, G).
However, MitoQ reduced the number of cells with a punctate
180 M.E. Solesio et al. / Biochimica et Biophysica Acta 1832 (2013) 174–182appearance of Bax in cell cultures that were challenged with 50 μM
6-OHDA (Fig. 5F,G). In addition, we corroborated the inhibitory effect
of MitoQ on 6-OHDA-induced translocation from mitochondrial frac-
tions by immunoblotting (Fig. 5H).
4. Discussion
In the present study,we have focused on assessing the effect ofMitoQ
on cellular pathways that contribute to 6-OHDA-induced mitochondrial
ﬁssion in SH-SY5Y cells. We utilized a sublethal 6-OHDA concentration
of 50 μM, which is able to induce mitochondrial morphological alter-
ations. We did not observe an increase in total protein carbonyls or inControl dTPP MitoQ
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Fig. 5. MitoQ reduces the 6-OHDA-induced mitochondrial translocation of Bax. SH-SY5Y ce
50 nM dTPP or MitoQ for 30 min, followed by a 12 h treatment with 50 μM 6-OHDA. Repre
are shown in A–F. Scale bar, 10 μm. G Percentages of cells with punctuate Bax distribution w
least three experiments, each performed in triplicate. Statistical signiﬁcance was determine
analysis of Bax levels in mitochondrial fractions obtained from SH-SY5Y cells. Cell cultures
with 50 μM 6-OHDA. Equal amounts of protein (30 μg/lane) were loaded on the gels. COX-
tative of three independent experiments.oxidative damage to mtDNA, suggesting that these levels of 6-OHDA
did not act by extensive oxidative damage but rather by relative mild
redox effects. Notably, MitoQ reduced themitochondrial morphology al-
terations induced by 6-OHDA. This suggests that a mild mitochondrial
redox process induced by 6-OHDA that can be prevented by MitoQ is
an early event in the change in mitochondrial morphology caused by
6HD. In addition, MitoQ prevented the 6-OHDA-induced translocation
of both Drp1 and Bax to mitochondria.
Pathology, toxicology, and genetics suggest that mitochondrial ox-
idative stress is an etiological factor in PD [7,8]. Under physiological
conditions, 6-OHDA is rapidly and non-enzymatically oxidized to
form ROS. Previous work in our group and elsewhere has shown anB 6-OHDA
D 6-OHDA+dTPP
F 6-OHDA+MitoQ
H
C 6-OHDA dTPP MitoQ
6-OHDA
Bax
COX IV
lls were transfected for 24 h with GFP-Bax vector, and were pre-treated (or not) with
sentative confocal images of mitochondrial morphology under the different conditions
ere determined 12 h after addition of 6-OHDA. Results shown are the mean±SEM of at
d by a two-tailed Student's test: n/s, p>0.05; **pb0.01. H. Representative immunoblot
were pre-treated with 50 nM dTPP or MitoQ for 30 min, followed by a 12 h treatment
IV was used as an index of mitochondrial load. The immunoblots shown are represen-
181M.E. Solesio et al. / Biochimica et Biophysica Acta 1832 (2013) 174–182increase in H2O2 in cell cultures challenged with 6-OHDA [31–34]. As
the 6-OHDA concentration used in our study was sublethal, and we
chose an early time point, SH-SY5Y cells challenged with 6-OHDA
did not present hallmarks of oxidative stress. Neither total protein
carbonyl group levels nor oxidative mtDNA damage levels were sig-
niﬁcantly modiﬁed by 6-OHDA. This suggests that the effects on the
cell were relatively mild redox signals probably originating in the mi-
tochondrial matrix in response to 6-OHDA oxidative stress, and this
was abrogated by pretreatment with MitoQ. In addition, we corrobo-
rated the lack of excessive oxidative stress in these conditions using
the ratiometric ﬂuorescent probe MitoPerOx for assessing mitochon-
drial phospholipid peroxidation.
Several classes of small molecular antioxidant mimetics have been
shown to protect against central nervous system injuries such as do-
paminergic neuron degeneration [25,35–38]. Neurons are metaboli-
cally active cells with high energy demands at locations distant
from the cell body. Because of this, these cells are particularly depen-
dent on mitochondrial function, as reﬂected by the observation that
mitochondrial-dysfunction diseases often have a neurodegenerative
component [23].
In vivo, MitoQ is taken up rapidly and extensively by mitochon-
dria, where it is reduced to the active antioxidant ubiquinol form
[10]. MitoQ is nontoxic and orally bioavailable in animal models and
humans [14,18]. MitoQ protects mitochondria by decreasing oxida-
tive damage to mitochondrial proteins, lipids, and DNA [11,12]. It
also has been shown to decrease mitochondrial damage and to
lower the levels of mitochondrial ROS in a range of animal models
(reviewed in [13]).
MitoQ blocks 6-OHDA inducedmitochondrial ﬁssion. By intervening
in this process, MitoQmodulates mitochondrial function. It enables mi-
tochondrial recruitment to critical subcellular compartments, content
exchange between mitochondria, mitochondrial shape control, com-
munication with the cytosol, and mitochondrial quality control. When
mitochondrial dynamics is disrupted, cellular dysfunction ensues.Mito-
chondrial ﬁssion is a highly regulated process, and is mediated by a6-OH
Drp1
B
MitoQ
H2O2
H2O2
Mitoch
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Fig. 6. Schematic diagram of the MitoQ-modulated abrogation of mitochondrial morphology
of H2O2, either extracellularly or within the cell, and this is able to reach the mitochondrial m
may activate the mitochondrial ﬁssion machinery, including the mitochondrial translocation
H2O2 increases in the mitochondrial matrix. MitoQ is effective at concentrations that do not
activation of the mitochondrial ﬁssion machinery by preventing Drp1 translocation to the m
response to 6-OHDA in SH-SY5Y cell cultures.deﬁned set of proteins [39–43]. Our data support the notion that
MitoQ blocks the activation of the mitochondrial ﬁssion machinery by
preventing mitochondrial translocation of Drp1, a large GTPase of the
dynamin family. Drp1 is cytosolic, but a subpopulation of the protein
migrates to mitochondria and accumulates at sites of future ﬁssion,
forming discrete spots [44,45]. According to in vitro studies, Drp1 as-
sembles into rings around mitochondria and constricts their mem-
branes. This results in degradation of the organelles in a GTP
hydrolysis-dependent manner [40]. In our study, 6-OHDA recruited
Drp1 to mitochondria. Confocal microscopy analysis of cell cultures
overexpressing Drp1-GFP revealed that addition of 6-OHDA modiﬁed
the cytosolic and diffuse distribution of Drp1, leading to a punctate mi-
tochondrial distribution. Administration of 50 nMMitoQ was sufﬁcient
to inhibit 6-OHDA-induced Drp1 mitochondrial translocation in
SH-SY5Y cells. This observation can be explained by the fact that
MitoQ is preventing posttranscriptional changes in Drp1. Accordingly,
redox modiﬁcation of Drp1 may link excessive mitochondrial ﬁssion
to neuronal injury in neurodegeneration [24,26]. In line with these ob-
servations, using a neurodegenerative model that monitors amyloid-β
toxicity to N2a cells, Manczak et al. have reported how MitoQ appears
to protect mitochondrial structure by preventing mitochondrial genes
from abnormal expression [25].
In addition, MitoQ abrogates the 6-OHDA-induced mitochondrial
translocation of Bax in SH-SY5Y cells. We and other groups have de-
scribed that Bax actively participates in neurodegenerative processes
[21,46]. Bax co-localized with Drp1 and Mfn2 at mitochondrial ﬁssion
sites in apoptotic cells [47], and has been suggested to participate directly
in apoptotic mitochondrial ﬁssion. Previously, in a different neurodegen-
erative model using MEF cell cultures from mice which lack Bax, we
have shown that this protein is not required for 6-OHDA-induced mito-
chondrial fragmentation [22]. Interestingly, MitoQ also mediates protec-
tion against cardiac ischemia–reperfusion injury, diabetic nephropathy,
adriamycin-induced cardiotoxicity, and hepatitis C-induced liver injury
[17,36–38] and whether prevention of mitochondrial ﬁssion contributes
to these processes will be an area of future activity (Fig. 6).p-quinones
DA H2O2
ax
ondrial
sion
alterations in the 6-OHDA PD model. Auto-oxidation of 6-OHDA leads to the formation
atrix. Mitochondrial ﬁssion induced by 6-OHDA-mediated stress is an early event. H2O2
of either Drp1 or Bax. MitoQ accumulated in the mitochondrial membrane may block
lead to induction of detectable oxidative stress hallmarks. MitoQ seems to prevent the
itochondria. In addition, MitoQ also blocked the formation of mitochondrial Bax foci in
182 M.E. Solesio et al. / Biochimica et Biophysica Acta 1832 (2013) 174–182In conclusion, our data suggest that 6-OHDA treatment leads to mi-
tochondrial fragmentation by inducing a mild redox stress on mito-
chondria that is sufﬁcient to induce a translocation of Drp1 to the
mitochondria and thereby increasemitochondrialﬁssion. This fragmen-
tation can be largely prevented by the mitochondria-targeted antioxi-
dant MitoQ, consistent with a mitochondrial redox signaling event
leading to Drp1 recruitment. Furthermore, these data suggest that
mitochondria-targeted antioxidants may be worth exploring as poten-
tial therapies in pathologies involving mitochondrial fragmentation.
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